Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with aids

Journal of Acquired Immune Deficiency Syndromes

Volumn 6, Issue 7, 1993, Pages 787-794

  Dezube, Bruce J ^a   Pardee, Arthur B ^a   Chapman, Beryl ^b   Beckett, Laurel A ^c   Korvick, Joyce A ^d   Novick, William J ^f   Chiurco, Jane ^f   Kasdan, Patricia ^e   Ahlers, Christoph M ^a   Ecto, Linda T ^b   Crumpacker, Clyde S ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Pediatric ACTG Operations Center   (United States)

^f SANOFI   (France)

Author keywords

Cytokines; HIV; Pentoxifylline; Triglycerides; Tumor necrosis factor

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; MESSENGER RNA; PENTAMIDINE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG MECHANISM; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS CULTURE; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BETA 2-MICROGLOBULIN; BIOPTERIN; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HIV; HUMAN; LEUKOCYTE COUNT; NEOPTERIN; PENTOXIFYLLINE; RNA, MESSENGER; SARCOMA, KAPOSI; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIGLYCERIDES; TUMOR NECROSIS FACTOR; VIRUS REPLICATION;

EID: 0027153107     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Dezube BJ, Pardee AB, Beckett LA, et al. Cytokine dysregulation in AIDS: the in vivo overexpression of mRNA of tumor necrosis factor-a and its correlation with that of the inflammatory cytokine GRO. J Acquir Immune Defic Syndr 1992; 5:1099-104.
2. Lahdevirta J, Maury CPJ, Teppo A-M, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:289-91.
3. Darling G, Fraker DL, Jensen JC, Gorschboth CM, Norton JA. Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 1990; 50:4008-13.
4. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987; 50:555-63.
5. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor αactivates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc Natl Acad Sci USA 1989; 86:5974-8.
6. Ito M, Baba M, Mori S, et al. Tumor necrosis factor antagonizes inhibitory effect of azidothymidine on human immunodeficiency virus (HIV) replication in vitro. Biochem Biophys Res Commun 1990; 166:1095-101.
7. Dezube BJ, Eder JP, Pardee AB. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Res 1990; 50:6806-10.
8. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34:50-97.
9. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155:1230-6.
10. Zabel P, Schonharting MM, Wolter DT, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989; 2:1474-7.
11. Dezube BJ, Fridovich-Keil JL, Bouvard I, Lange RF, Pardee AB. Pentoxifylline and wellbeing in patients with cancer. Lancet 1990; 335:662.
12. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78:1205-11.
13. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 1990; 75:1011-6.
14. Peterson PK, Gekker G, Chao CC, et al. Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-α-mediated mechanism. J Clin Invest 1992; 89:574-80.
15. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991; 77:1653-6.
16. Grunfeld C, Kotier DP, Hamadeh R, Tierney A, Wang J, Pierson R Jr. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
17. Grunfeld C, Kotier DP, Shigenaga JK, et al. Circulating interferon-αlevels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90:154-62.
18. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E III, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6:344-50.
19. Grunfeld C, Kotler DP. The wasting syndrome and nutritional support in AIDS. Semin Gastrointest Dis 1991; 2:25-36.
20. Semb H, Peterson J, Tavernier J, et al. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987; 62:8390-4.
21. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322:166-72.
22. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316:379-85.
23. Rieckmann P, Poli G, Kehrl JH, Fauci AS. Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1. J Exp Med 1991; 173:1-5.
24. Wang AM, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985; 228:149-54.
25. Cleveland DW, Lopata MA, MacDonald RJ, Cowan NJ, Rutter WJ, Kirschner MW. Number and evolutionary conservation of α- and β-tubulin and cytoplasmic β- and -γ-actin genes using specific cloned cDNA probes. Cell 1980; 20:95-105.
26. Hollinger FB, Bremer JW, Myers L, Gupta P, Meyer W. HIV quantitation by dilutional microculture: development, standardization, and quality control implementation in a multicenter clinical trials setting, [Abstract]. Presented at the VIII International Conference on AIDS, Amsterdam, the Netherlands, 1992.
27. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989; 321:1621-5.
28. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor a functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990; 87:782-5.
29. Wright SC, Jewett A, Mitsuyasu R, Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol 1988; 141:99-104.
30. Lathey JL, Agosti JM, Nelson JA, et al. A selective defect in tissue factor mRNA expression in monocytes from AIDS patients. Clin Immunol Immunopathol 1990; 54:1-13.
31. Voth R, Rossol S, Klein K, et al. Differential gene expression of Ifn-αand tumor necrosis factor-αin peripheral blood mononuclear cells from patients with AIDS related complex and AIDS. J Immunol 1990; 144:970-5.
32. Hommes MJT, Romijn JA, Godfried MH, et al. Increased resting energy expenditure in human immunodeficiency virus-infected men. Metabolism 1990; 39:1186-90.
33. Reddy MM, Sorrell SJ, Lange M, Grieco MH. Tumor necrosis factor and HIV p24 antigen levels in serum of HIV-infected populations. J Acquir Immune Defic Syndr 1988; 1:436-40.
34. Jones PD, Shelley L, Wakefield D. Tumor necrosis factor-αin advanced HIV infection in the absence of AIDS-related secondary infections. J Acquir Immune Defic Syndr 1992; 5:1266-71.
35. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985; 135:3972-7.
36. Aderka D, Engelmann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991; 51:5602-7.
37. Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advance AIDS-related complex. Lancet 1992; 339:453-6.
38. Katzenstein DA, Holodniy M, Israelski DM, et al. Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. J Acquir Immune Defic Syndr 1992; 5:107-12.
39. Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 76:2303-10.